Compass Therapeutics Inc. stocks have been trading down by -37.91 percent after mixed clinical trial and funding setback headlines.
Click Here for a Millionaire's POV on Trading CMPX
SUBSCRIBE FOR ALERTSJOIN 50,000+ ACTIVE TRADERS
Key Takeaways
- CMPX has pulled back from the $2.40 area to around $1.80, putting recent buyers under pressure.
- Intraday action shows extreme volatility, with Compass Therapeutics Inc. dipping below $1.00 before bouncing, a classic high-risk trading setup.
- CMPX holds about $179.9M in cash and short-term investments against modest debt, giving the company meaningful runway.
- Compass Therapeutics Inc. continues to post steep losses, so traders are weighing strong liquidity against ongoing cash burn.
- CMPX charts now sit near a key support zone where prior moves have reversed or accelerated.
Live Update At 09:17:25 EDT: On Tuesday, September 22, 2026 Compass Therapeutics Inc. stock [NASDAQ: CMPX] is trending down by -37.91%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Quick Financial Overview
CMPX is a classic early‑stage biotech profile: strong cash, heavy losses, and a stock chart that trades like a rollercoaster. On the daily chart, Compass Therapeutics Inc. has faded from roughly $2.40 at the end of August 2026 to about $1.82 on 2026/09/21. That steady grind lower tells traders momentum has shifted from buyers to sellers over several weeks.
Financially, CMPX is not a revenue story yet. The most recent quarterly report shows a net loss of about $25.2M, or roughly -$0.13 per share. Research and development for Compass Therapeutics Inc. ran near $19.6M, with another $7.4M in general and administrative expense. This is a company spending aggressively to advance its pipeline.
More Breaking News
- Ondas (ONDS) Expands Defense Footprint With Aggressive Acquisitions
- GDC Stock Holds Range As Traders Watch Volatility
- HL Stock Holds Ground As Street Backs Low-Cost Silver Leader
- Rambus (RMBS) Stock Climbs As Wall Street Engagement Deepens
The upside for CMPX is its balance sheet. Compass Therapeutics Inc. carries around $179.9M in cash and short-term investments against only about $8.0M in long-term debt. A current ratio above 11 signals plenty of near‑term liquidity. For traders, that means CMPX is less about bankruptcy risk and more about timing sentiment swings around the chart.
Why Traders Are Watching CMPX Price Action
CMPX draws momentum traders because the tape moves. The 5‑minute chart shows Compass Therapeutics Inc. trading calmly around $1.83–$1.86 in the early premarket, then suddenly unraveling. Once liquidity thinned and stop orders hit, CMPX flushed to the $0.85 area before bouncing back into the $1.10–$1.20 range. That kind of intraday range compresses days of volatility into an hour.
For short‑term traders, this is textbook emotional selling. CMPX opened near prior levels, cracked support, triggered panic, then attracted bargain hunters and shorts covering into the washout. When Compass Therapeutics Inc. moves like this, the edge comes from preparation—mapping your levels before the chaos hits, not during it.
On the multi‑day chart, CMPX shows a slow bleed from the $2.40s to the high $1.80s and now the low $1.80s. Each bounce for Compass Therapeutics Inc. has been weaker than the last. That tells trend traders the path of least resistance remains down until CMPX can reclaim prior resistance levels and hold them.
At the same time, the fundamentals give a different kind of support. CMPX has more than $166.0M in stockholders’ equity and working capital above $160.0M. With only 35 employees and significant cash, Compass Therapeutics Inc. has room to keep funding trials. Traders know biotech headlines can hit at any time, but until then, CMPX trades mostly on charts, psychology, and sector mood.
Conclusion
CMPX sits at an important crossroads. On one side, Compass Therapeutics Inc. carries a cleaner balance sheet than many micro‑cap biotechs, with low debt and a cash cushion big enough to fund ongoing research. On the other, CMPX continues to post sizeable quarterly losses, and the market has been marking the stock down for weeks. That tension between runway and red ink is exactly what creates these wild trading ranges.
For active traders, CMPX is not a slow, sleepy ticker. The intraday collapse under $1.00 and sharp rebound show how fast sentiment can flip when Compass Therapeutics Inc. hits crowded levels. The key is discipline. Know your risk, know your levels, and avoid chasing every spike. As Tim Bohen, lead trainer with StocksToTrade says, “A good trade setup checks all the boxes—volume, trend, catalyst. Don’t trade if you’re missing pieces of the puzzle.” Keeping that checklist in mind can help traders filter the most volatile CMPX moves from the ones that truly fit their playbook.
CMPX will likely stay on watchlists as long as Compass Therapeutics Inc. holds its cash‑rich, low‑debt profile while the chart trades this heavy. Biotech names like CMPX can reward preparation but punish stubbornness. As Tim Sykes likes to remind his students, “Cut losses quickly, because holding and hoping is not a strategy.” For traders studying CMPX, that mindset matters more than any single trade.
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.